MEDICINA
Departamento
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (10)
2024
2023
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
American Journal of Hematology
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
2020
-
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518
2013
-
Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
Haematologica, Vol. 98, Núm. 6, pp. 980-987
2012
-
Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders
Haematologica, Vol. 97, Núm. 8, pp. 1272-1277
2009
-
Plitidepsin is active in peripheral T-cell lymphoma: A subset analysis from an ongoing multicenter phase II trial
Haematologica Meeting Reports